Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 477

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 477
---
 furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Aadi electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Aadi are inactive textual references and except as specifically incorporated by reference into this proxy statement, information on those websites is not part of this proxy statement. Aadi has filed this proxy statement with the SEC, including the attached annexes, exhibits and schedules, which contains additional relevant information about Aadi and Aadi common stock. - 322 -

If you would like to request documents from Aadi, please send a request in writing or by
telephone at the following addresses:

Aadi Bioscience, Inc.

17383 Sunset Boulevard Suite A250

Pacific Palisades, California 90272

Attn: Corporate Secretary

Tel:
(424) 744-8055

Email: [●]

If you are an Aadi stockholder and would like additional copies, without charge, of this proxy statement or if you have questions about the
proposals contained herein, including the procedures for voting your shares, you should contact Aadi’s proxy solicitor, Sodali & Co, at the following address and telephone number:

SODALI & CO

430 Park Avenue,
14th Floor

New York, NY 10022

Email: AAADI@investor.sodali.com

Banks and Brokers Call: (203) 658-9400

Stockholders Call Toll Free: (800) 662-5200

- 323 -

AADI BIOSCIENCE, INC.’S FINANCIAL STATEMENTS Index to Financial Statements

| Audited Financial Statements for the Years Ended December 31, 2023 and 2022                   |     |      |
|:----------------------------------------------------------------------------------------------|:----|:-----|
| Report of Independent Registered Public Accounting Firm                                       |     | F-2  |
| Consolidated Balance Sheets as of December 31, 2023 and                                       
 2022                                                                                          |     | F-4  |
| Consolidated Statements of Operations and Comprehensive Loss for the Years ended              
 December 31, 2023 and 2022                                                                    |     | F-5  |
| Consolidated Statements of Stockholders’ Equity for the Years ended December 31,              
 2023 and 2022                                                                                 |     | F-6  |
| Consolidated Statements of Cash Flows for the Years ended December